Vitrafy Life Sciences (ASX: VFY) has entered the US cell and gene therapy market through a six-month agreement with Charter Medical, based in North Carolina. Vitrafy will install its advanced cryopreservation system at Charter’s Innovation Hub, enhancing cold chain logistics and cell therapy development. The system includes the Guardion mobile freezing units and the LifeChain cloud platform, designed to optimize freeze profiles and capture processing data for better outcomes. This collaboration marks a significant step for Vitrafy, showcasing its technology to a broader audience in the high-value biopharma segment and paving the way for future partnerships in the industry. The deployment is expected to start in the second half of the 2027 financial year.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://smallcaps.com.au/article/vitrafy-life-sciences-enters-us-cell-and-gene-therapy-space-with-cryopreservation-agreement
